2.07 USD
+0.14 (+7.25%)
2.12 USD
+0.05 (+2.42%)
Overall IPA gets a fundamental rating of 2 out of 10. We evaluated IPA against 58 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of IPA have multiple concerns. IPA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
IPA had negative earnings in the past year.
IPA had a negative operating cash flow in the past year.
In the past 5 years IPA always reported negative net income.
In the past 5 years IPA always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -68.03%, IPA is doing worse than 89.09% of the companies in the same industry.
IPA has a worse Return On Equity (-127.97%) than 83.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.03% | ||
| ROE | -127.97% | ||
| ROIC | N/A |
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IPA has a better Gross Margin (55.25%) than 65.45% of its industry peers.
In the last couple of years the Gross Margin of IPA has remained more or less at the same level.
IPA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IPA has more shares outstanding
The debt/assets ratio for IPA is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.35, we must say that IPA is in the distress zone and has some risk of bankruptcy.
IPA has a worse Altman-Z score (-0.35) than 76.36% of its industry peers.
IPA has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
IPA's Debt to Equity ratio of 0.49 is on the low side compared to the rest of the industry. IPA is outperformed by 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.35 |
ROIC/WACCN/A
WACC10.11%
2.3 Liquidity
A Current Ratio of 2.08 indicates that IPA has no problem at all paying its short term obligations.
IPA's Current ratio of 2.08 is in line compared to the rest of the industry. IPA outperforms 43.64% of its industry peers.
IPA has a Quick Ratio of 1.85. This is a normal value and indicates that IPA is financially healthy and should not expect problems in meeting its short term obligations.
IPA has a Quick ratio (1.85) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.08 | ||
| Quick Ratio | 1.85 |
3. Growth
3.1 Past
IPA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.78%, which is quite impressive.
The Revenue has been growing slightly by 0.01% in the past year.
Measured over the past years, IPA shows a quite strong growth in Revenue. The Revenue has been growing by 11.77% on average per year.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%
3.2 Future
IPA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.31% yearly.
Based on estimates for the next years, IPA will show a quite strong growth in Revenue. The Revenue will grow by 17.92% on average per year.
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IPA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IPA's earnings are expected to grow with 35.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.39%
EPS Next 3Y35.81%
5. Dividend
5.1 Amount
IPA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.07
+0.14 (+7.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners8.61%
Inst Owner Change2.35%
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap95.53M
Revenue(TTM)24.52M
Net Income(TTM)-30.23M
Analysts80
Price Target5.1 (146.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.31%
Min EPS beat(2)0.99%
Max EPS beat(2)87.62%
EPS beat(4)3
Avg EPS beat(4)14.95%
Min EPS beat(4)-35.01%
Max EPS beat(4)87.62%
EPS beat(8)6
Avg EPS beat(8)14.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.96%
Min Revenue beat(2)-12.4%
Max Revenue beat(2)-7.52%
Revenue beat(4)0
Avg Revenue beat(4)-12.13%
Min Revenue beat(4)-22.81%
Max Revenue beat(4)-5.81%
Revenue beat(8)3
Avg Revenue beat(8)-4.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10%
EPS NY rev (1m)-36.36%
EPS NY rev (3m)-36.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.34%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.6 | ||
| P/tB | 9.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.38
BVpS0.37
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.03% | ||
| ROE | -127.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.25% | ||
| FCFM | N/A |
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
F-Score4
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15.61% | ||
| Cap/Sales | 3.26% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.08 | ||
| Quick Ratio | 1.85 | ||
| Altman-Z | -0.35 |
F-Score4
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)20.78%
Cap/Depr(5y)25.53%
Cap/Sales(3y)5.4%
Cap/Sales(5y)5.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%
EBIT growth 1Y12.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.97%
OCF growth 3YN/A
OCF growth 5YN/A
IMMUNOPRECISE ANTIBODIES LTD / IPA FAQ
What is the ChartMill fundamental rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to IPA.
Can you provide the valuation status for IMMUNOPRECISE ANTIBODIES LTD?
ChartMill assigns a valuation rating of 1 / 10 to IMMUNOPRECISE ANTIBODIES LTD (IPA). This can be considered as Overvalued.
What is the profitability of IPA stock?
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a profitability rating of 1 / 10.
Can you provide the financial health for IPA stock?
The financial health rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) is 2 / 10.
Can you provide the expected EPS growth for IPA stock?
The Earnings per Share (EPS) of IMMUNOPRECISE ANTIBODIES LTD (IPA) is expected to grow by 49.5% in the next year.